Drug General Information |
Drug ID |
D0L5MW
|
Former ID |
DNC010258
|
Drug Name |
(+/-)-nantenine
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Canonical SMILES |
CC(=O)C1=CC2=C3C(CC4=CC5=C(C=C4C3=C1C(=O)C)OCO5)N(CC2)C
|
InChI |
1S/C22H21NO4/c1-11(24)15-6-13-4-5-23(3)17-7-14-8-18-19(27-10-26-18)9-16(14)22(21(13)17)20(15)12(2)25/h6,8-9,17H,4-5,7,10H2,1-3H3
|
InChIKey |
QBCMSGDOKGQABG-UHFFFAOYSA-N
|
Target and Pathway |
Target(s) |
D(4) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-2C adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 7 receptor |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 2B receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 6 receptor |
Target Info |
Inhibitor |
[1]
|
Dopamine D1 receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 1D receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
D(3) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
D(1B) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
Histamine H2 receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 5A receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-1B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
Beta-1 adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 1B receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 2C receptor |
Target Info |
Inhibitor |
[1]
|
Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04022:cGMP-PKG signaling pathway
|
Neuroactive ligand-receptor interactionhsa04015:Rap1 signaling pathway
|
cAMP signaling pathway
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholismhsa04014:Ras signaling pathway
|
Calcium signaling pathway
|
Serotonergic synapsehsa04726:Serotonergic synapsehsa04022:cGMP-PKG signaling pathway
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
cGMP-PKG signaling pathway
|
AMPK signaling pathway
|
Adrenergic signaling in cardiomyocytes
|
Vascular smooth muscle contraction
|
Salivary secretionhsa04020:Calcium signaling pathway
|
Serotonergic synapse
|
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
Amphetamine addiction
|
Morphine addiction
|
Alcoholismhsa04024:cAMP signaling pathway
|
Salivary secretionhsa04080:Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
Estrogen signaling pathway
|
Morphine addictionhsa04020:Calcium signaling pathway
|
Dopaminergic synapsehsa04020:Calcium signaling pathway
|
Gastric acid secretionhsa04020:Calcium signaling pathway
|
Endocytosis
|
Salivary secretion
|
Dilated cardiomyopathyhsa04024:cAMP signaling pathway
|
Inflammatory mediator regulation of TRP channelshsa04022:cGMP-PKG signaling pathway
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_11:TCR Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathwayP00002:Alpha adrenergic receptor signaling pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04373:5HT1 type receptor mediated signaling pathway
|
5HT2 type receptor mediated signaling pathway
|
5HT3 type receptor mediated signaling pathway
|
5HT4 type receptor mediated signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP05912:Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Enkephalin releaseP05912:Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Histamine H2 receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Beta1 adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
Pathway Interaction Database
|
IL4-mediated signaling eventslysophospholipid_pathway:LPA receptor mediated events
|
PathWhiz Pathway
|
Excitatory Neural Signalling Through 5-HTR 7 and SerotoninPW000444:Excitatory Neural Signalling Through 5-HTR 6 and SerotoninPW000440:Dopamine Activation of Neurological Reward SystemPW000449:Intracellular Signalling Through Histamine H2 Receptor and Histamine
|
Gastric Acid ProductionPW000564:Muscle/Heart Contraction
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
Adrenaline,noradrenaline inhibits insulin secretion
|
G alpha (i) signalling events
|
G alpha (z) signalling events
|
Surfactant metabolismR-HSA-390651:Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (s) signalling eventsR-HSA-390696:Adrenoceptors
|
G alpha (z) signalling eventsR-HSA-390696:Adrenoceptors
|
G alpha (q) signalling events
|
G alpha (12/13) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (12/13) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
G alpha (s) signalling eventsR-HSA-390650:Histamine receptors
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
G alpha (q) signalling eventsR-HSA-390696:Adrenoceptors
|
Surfactant metabolism
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic Neurons
|
GPCRs, OtherWP58:Monoamine GPCRs
|
Platelet Aggregation (Plug Formation)
|
Integration of energy metabolism
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
Nicotine Activity on Dopaminergic NeuronsWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
|
GPCRs, OtherWP727:Monoamine Transport
|
SIDS Susceptibility Pathways
|
NRF2 pathway
|
Synaptic Vesicle Pathway
|
Serotonin Transporter ActivityWP58:Monoamine GPCRs
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
Calcium Regulation in the Cardiac Cell
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
Endothelin Pathways
|
AMPK SignalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
GPCRs, OtherWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
|
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
|
GPCRs, OtherWP69:TCR Signaling Pathway
|
Peptide GPCRs
|
Opioid Signalling
|
Secretion of Hydrochloric Acid in Parietal Cells
|
Vitamin D Receptor Pathway
|
AMPK SignalingWP58:Monoamine GPCRs
|
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
References |
REF 1 | Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. |